Economic Evaluations and Health Economic Models of Gliomas: A Systematic Review of the Literature (ISPOR poster code: SA56)

PRISMA flow diagram



TABLE 4.: STUDIES INVESTIGATING OTHER TYPES OF INTERVENTIONS

Reference	Study country	Model type	Health states (if relevant)	Investigated technologies	Patient population
Baguet, 2019	Belgium	Decision tree cohort model	Responder; Real responder; Non-responder; Real non-responder; Non-real responder; Non-real non-responer; False responder; False non-responder	**Follow-up [18F] FET PET vs. MRI**	Patients with newly diagnosed GB who underwent resection
Chandra 2019	USA	The model type is not specified, but it is assumed to be a decision tree cohort model.	No data	Medicaid group vs. Non-Medicaid group (Medicare and private insurance)	Patients with newly diagnosed GB undergoing their first resection
Voigt, 2016	USA	Decision tree cohort mode	No data	**Brain laser interstitial thermal therapy** vs. Current treatments (collectively craniotomy ± gliadel wafer, plus biopsy)	Patients with primary or recurrent GB

18F-FET PET: O-(2-18F-fluoroethyl)-L-tyrosine Positron Emission Tomography; MRI: Magnetic Resonance Imaging; QALY: quality-adjusted life years; LYG: Life years gained; GB: glioblastoma

References

1. Baguet, T., Verhoeven, J., De Vos, F., & Goethals, I. (2019). Cost-Effectiveness of [18F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma. *Frontiers in Oncology*, 9, 814.
2. Bernard-Arnoux, F., Lamure, M., Ducray, F., Aulagner, G., Honnorat, J., & Armoiry, X. (2016). The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. *Neuro-oncology*, 18(8), 1129–1136.
3. Chandra, A., Young, J. S., Dalle Ore, C., Dayani, F., Lau, D., Wadhwa, H., Rick, J. W., Nguyen, A. T., McDermott, M. W., Berger, M. S., & Aghi, M. K. (2020). Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma. *Journal of Neurosurgery*, *133*(1), 89–99.
4. Chen J, Tong X, Han M, Zhao S, Ji L, Qin Y, He Z, Pan Y, Wang C, Liu A. Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States. *Front Pharmacol*. 2021 Sep 27;12:743979.
5. Connock, M., Auguste, P., Dussart, C., Guyotat, J., & Armoiry, X. (2019). Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. *Journal of Neuro-oncology*, 143(3), 605–611.
6. Connock, M., Auguste, P., & Armoiry, X. (2021). A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. *The European Journal of Health*. 22(1), 89–100.
7. de Rivera Guzman, J. Nino, et al. "EE363 Cost-Effectiveness Analysis of Adding Tumor Treating Fields Therapy to Temozolomide Versus Temozolomide Only in Patients with Glioblastoma in France." *Value in Health* 26.12 (2023): S121.
8. Diebold, G., Ducray, F., Henaine, A.-M., Frappaz, D., Guyotat, J., Cartalat-Carel, S., Breant, V., Fouquet, A., Aulagner, G., Honnorat, J., & Armoiry, X. (2014). Management of glioblastoma: Comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. *Journal of Clinical Pharmacy and Therapeutics*, *39*(6), 642–648.
9. Fischer, A. Cost-Effectiveness Of Bevacizumab Concomitant With The Standard Of Therapy For Newly Diagnosed Glioblastoma. Diss. The University of Western Ontario (Canada), 2016.
10. Garcia Lopez, J. L., Rodriguez, B. J., Puig-Junoy, J., & Carrato, M. A. (2014). Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain. *Value in Health*. 17(7), A638.
11. Ghosh, S., Baker, S., De Castro, D. G., Kepka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Dyttus-Cebulok, K., Rosenblatt, E., Fidarova, E., & Roa, W. (2018). Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma. *Radiotherapy and Oncology*, *127*(1), 114–120.
12. Guzauskas, G. F., Pollom, E. L., Stieber, V. W., Wang, B. C. M., & Garrison, L. P., Jr (2019). Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. *Journal of Medical Economics*, 22(10), 1006–1013.
13. Kovic, B., & Xie, F. (2015). Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(20), 2296–2302.

14. Krysanov, I., & Krysanova, V. (2013). Pharmacoeconomic analysis of intravenous temozolomide for the treatment of newly diagnosed glioblastoma multiforme in Russia. *Value in Health*, *16*(7), A413.
15. Lamers, L. M., Stupp, R., Van Den Bent, M. J., Al, M. J., Gorlia, T., Wasserfallen, J., Mittmann, N., Jin Seung, S., Crott, R., & Uyl-de Groot, C. A. (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: A report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. *Cancer*, *112*(6), 1337–1344.
16. Martikainen, J. A., Kivioja, A., Hallinen, T., & Vihinen, P. (2005). Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. *PharmacoEconomics*, 23(8), 803–815.
17. Messali, A., Hay, J. W., & Villacorta, R. (2013). The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. *Neuro-oncology*, 15(11), 1532–1542.
18. NICE. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. 2017. Available at (Last accessed on 08.11.2024.): https://www.nice.org.uk/guidance/ta121
19. Norum, J. (1996). Radiotherapy costs in glioblastoma. *Oncology Reports*, *3*(4), 777–780.
20. Ranjan, T., Yu, A., Elhamdani, S., Howard, C. M., Lirette, S. T., Denning, K. L., Valluri, J., & Claudio, P. P. (2023). Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients' healthcare costs. *Neuro-Oncology Advances*, *5*(1), vdad055.
21. Roussakow, S. V. (2017). Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: A retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. *BMJ Open*, *7*(11), e017387.
22. Ruiz-Sánchez, D., Peinado, I. I., Alaguero-Calero, M., Sastre-Heres, A. J., Diez, B. G., & Peña-Díaz, J. (2016). Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. *Oncology Letters*, *12*(3), 1935–1940.
23. Voigt, J. D., & Barnett, G. (2016). The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible. *Cost effectiveness and Resource Allocation*, 14(1), 6.
24. Waschke, A., Arefian, H., Walter, J., Hartmann, M., Maschmann, J., & Kalff, R. (2018). Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. *Journal of Neuro-oncology*, 138(2), 359–367.